13235-83-1

Basic information

• Product Name: 1-(4-bromophenyl)propan-2-amine
• Synonyms: 1-(4-bromophenyl)propan-2-amine;4-BROMO-A-METHYL-BENZENEETHANAMINE;BenzeneethanaMine, 4-broMo-a-Methyl-;Benzeneethanamine,4-bromo-α-methyl-
• CAS NO: 13235-83-1
• Molecular Formula: C₉H₁₂BrN
• Molecular Weight: 214.105
• Mol File: 13235-83-1.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 272.2°C at 760 mmHg
• Flash Point: 118.5°C
• Appearance: /
• Density: 1.346g/cm³
• Vapor Pressure: 0.00615mmHg at 25°C
• Refractive Index: 1.562
• PKA: 9.76±0.10(Predicted)
• CAS DataBase Reference: 1-(4-bromophenyl)propan-2-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-bromophenyl)propan-2-amine(13235-83-1)
• EPA Substance Registry System: 1-(4-bromophenyl)propan-2-amine(13235-83-1)

Safety Data

• Hazardous Substances Data: 13235-83-1(Hazardous Substances Data)

Usage

General Description

1-(4-bromophenyl)propan-2-amine, also known as 4-Bromoamphetamine, is a synthetic compound that falls under the amphetamine class of drugs. It is primarily used for its psychoactive effects and is known to have stimulant and entactogenic properties. The chemical structure consists of a phenyl ring with a bromine substitution at the para position, attached to a propan-2-amine molecule. 4-Bromoamphetamine is not approved for medical use, and its recreational use is known to pose significant health risks, including neurotoxicity and potential addiction. It is classified as a controlled substance in many countries due to its potential for abuse and harmful effects on the central nervous system.

InChI:InChI=1/C9H12BrN/c1-7(11)6-8-2-4-9(10)5-3-8/h2-5,7H,6,11H2,1H3

Upstream product

• 4489-23-0 1-bromo-4-(prop-1-en-1-yl)benzene 
• 6186-22-7 4-bromophenyl acetone 
• 1310-73-2 sodium hydroxide 
• 7732-18-5 water 
• 108-86-1 bromobenzene 
• 1122-91-4 4-bromo-benzaldehyde 
• 131981-75-4 (E)-1-bromo-4-(2-nitroprop-1-en-1-yl)benzene 
• 21892-60-4 1-(p-Bromphenyl)-2-nitro-1-propen 
• 744221-06-5 1-bromo-4-(2-chloro-propyl)-benzene 

Downstream Products

• 1146547-07-0 C₁₇H₁₈BrNO₂ 
• 1233524-85-0 methyl (1-(4-bromophenyl)propan-2-yl)carbamate 
• 869567-02-2 (S)-(+)-1-(4'-bromo)phenyl-2-propanamine 
• 869567-01-1 (R)-(-)-1-(4'-bromo)phenyl-2-propanamine 
• 1446021-11-9 N-(1-(4-(azetidin-3-yl)phenyl)propan-2-yl)acetamide 
• 1446021-05-1 tert-butyl 3-(4-(2-acetamidopropyl)phenyl)azetidine-1-carboxylate 
• 1446020-02-5 C₂₂H₂₆F₂N₄O₂ 
• 1446019-91-5 C₂₄H₂₅ClN₄O 
• 1446019-65-3 C₂₂H₂₉N₃O₂ 
• 1446019-89-1 N-(1-(4-(1-(5-bromopyrimidin-2-yl)azetidin-3-yl)phenyl)propan-2-yl)acetamide 
• 1446019-54-0 N-(1-(4-(1-(4-propoxyphenyl)azetidin-3-yl)phenyl)propan-2-yl)acetamide 
• 1197684-85-7 N-[2-(4-bromophenyl)-1-methyl-ethyl]acetamide 
• 113682-47-6 N-(1-(4-iodophenyl)propan-2-yl)acetamide 
• 1351781-75-3 (R)-N-[2-(4'-bromophenyl)-1-methylethyl]-2-methoxyacetamide 

Relevant articles and documents

Direct Access to Primary Amines from Alkenes by Selective Metal-Free Hydroamination

Direct and selective synthesis of primary amines from easily available precursors is attractive yet challenging. Herein, we report the rapid synthesis of primary amines from alkenes via metal-free regioselective hydroamination at room temperature. Ammonium carbonate was used as ammonia surrogate for the first time, allowing for efficient conversion of terminal and internal alkenes into linear, α-branched, and α-tertiary primary amines under mild conditions. This method provides a straightforward and powerful approach to a wide spectrum of advanced, highly functionalized primary amines which are of particular interest in pharmaceutical chemistry and other areas.

INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF

The present invention provides PRMT5 inhibitors of Formula (I), wherein R1 is a non-hydrogen monovalent group; W is a direct bond or -NH-; T, U, and V are independently of each other selected from C and N; R2 is H or a halo; m is 1 or 2; X is a carbon, a nitrogen, or an oxygen; Y is C or N; Z is a direct bond or a carbon; R3 is H, a non-hydrogen monovalent group, an oxo group, a bivalent spiro ring-forming group, or a bivalent bridge-forming group; n is 1 or 2; and Formula (II) stands for a single bond or a double bond. Pharmaceutical products comprising the PRMT5 inhibitors and use thereof in treating proliferative disorders such as cancer, metabolic disorders, blood disorders, autoimmune diseases, and inflammatory diseases are also provided.

NEW AZETIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

The invention relates to new azetidine derivatives of the formula (I), to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.